| | Latest Acquisitions and Expansions
in Large Molecule Capabilities |
|
| Catalent to Invest $350 Million in Integrated Biologics
Drug Substance and Drug Product Manufacturing at
Bloomington, Indiana, Facility |
|
| On the heels of its recent acquisition of a biologics development and manufacturing facility undergoing construction near to Oxford in the U.K., Catalent announced a multi-year $350 million investment at its facility in Bloomington, to add new bioreactors, syringe filling lines, and additional lyophilization capacity, supported by quality control laboratories and complex |
|
| automated packaging. Both investments will serve the biopharmaceutical industry’s robust pipeline, and expand both biologics drug substance and drug product capacity and capabilities. |
|
| | | Catalent Acquires Commercial-Scale Cell Therapy Development and Manufacturing Facility in
Princeton, New Jersey, from Erytech |
|
| Catalent recently acquired from Erytech Pharma its state-of-the-art, commercial-scale cell therapy manufacturing facility in Princeton, for $44.5 million. The deal includes an exclusive long-term supply agreement for Catalent to support Erytech’s lead product candidate eryaspase (GRASPA®), a red blood cell-derived product, which is currently in late-stage development for the treatment of acute lymphoblastic leukemia. |
|
| | | Latest Acquisitions and Expansions
in Small Molecule Capabilities |
|
| Catalent Adds New High-Throughput Encapsulation Manufacturing Suites at Kansas City, Missouri, Facility |
|
| Catalent has completed the installation and commissioning of four new high throughput ‘high-bay’ CGMP manufacturing suites at its facility in Kansas City, Missouri, to increase its capacity and capabilities for producing oral solid dose forms. |
|
| | | Catalent Also Expands Nasal Drug Development and Manufacturing Capabilities at RTP, North Carolina, Facility |
|
| With an aim to provide world-class services for the development and manufacturing of unit and bi-dose nasal spray products, Catalent completed a significant expansion of its nasal capabilities at its Morrisville, Research Triangle Park (RTP), North Carolina, facility. |
|
| This marks the first phase of a multi-million-dollar investment at the site to expand and modernize its nasal drug delivery capabilities, substantially increasing technology and capacity to support projected growth for existing and future customers. The expansion is in response to the growing interest in the potential for nose-to-brain drug administration, and as an alternative route for the delivery of systemic drugs, rescue therapies, and vaccines. |
|
| | | Catalent Publishes Third Annual
Corporate Responsibility Report |
|
| Catalent’s third annual Corporate Responsibility Report for Fiscal 2021 is now public! Through what was yet another extraordinary year, the company made progress in areas such as carbon reduction, community investment and diversity and inclusion. We remain steadfastly true to the core values of always putting people and patients first. |
|
| | | | | The Medicine Maker: The Power List 2022
Catalent’s Chair and CEO, John Chiminski, has been celebrated as one of the top 10 leaders in small molecules in a recent survey about the influential people making the most impact in the drug-making space. | | Read More on TheMedicineMaker.com |
|
| | | Contract Pharma: Pharma & Biopharma Trends CDMOs Face in 2022 and Beyond Contract Pharma recently interviewed Elliott Berger, Catalent’s Chief Marketing Officer, who shared his thoughts about the key trends that will affect pharma & biopharma CDMOs in the near future. | | Read More on ContractPharma.com |
|
| | | Biopharma-reporter: Catalent buys UK vaccine manufacturing centre Catalent is acquiring the U.K.’s Vaccine Manufacturing and Innovation Centre in Harwell, Oxfordshire. | | Read More on biopharma-reporter.com |
|
| | | Genetic Engineering & Biotechnology News (GEN):
Going Digital Can Help CDMOs Upgrade Their Value Propositions Chris Demers, Ph.D., principal automation and data scientist, Catalent, discusses why Catalent is investing in connected technologies to use real-time data to run its business through the creation of a connected enterprise. | | Read More on Genengnews.com |
|
| Upcoming Events: Join Our Experts to Hear the Latest on Technology Development Programs |
|
| | | Biologics
BIO International Convention 2022 | San Diego Convention Center – San Diego, CA | June 13-16, 2022
Stop by booth 1227 to meet the Catalent team and join Catalent’s seasoned experts for speaking sessions and panel discussions throughout the BIO International Convention in San Diego.
Schedule a Meeting
Cell and Gene Therapy
ASGCT 25th Annual Meeting| Walter E. Washington Convention – Washington, DC (Hybrid Conference) | May 16-19, 2022
Visit the Catalent Cell & Gene Therapy team in booth 234 and hear our expert , George Buchman, Ph.D., VP, Pre-clinical and Process Development, will present "AAV Platform Process Accelerating Production from Gene to Clinic" on May 17.
Schedule a Meeting
ISSCR Annual Meeting 2022 | Moscone Center West – San Francisco | June 15-18, 2022 Meet Catalent experts at booth 132 and hear Boris Greber, Ph.D., Head of Research & Development, iPCS, Catalent Cell & Gene Therapy share his thoughts about GMP-Compliant iPSC lines and Differentiation Workflows for Cell Therapy and How Catalent is developing an HLA-homozygous (HLA-h) universal cell bank from cord blood units accounting for key regulatory aspects such as donor eligibility and consent, GMP manufacturing and commercial use consent. Schedule a Meeting
Clinical Supply Services
BSMA Annual Conference 2022 | Foster City, California | June 22-23, 2022 Join Catalent’s Nicole Gray, Director, Strategic Supply Solutions, who will discuss the key to successfully implement direct-to-patients clinical studies. At the same conference, Ann McMahon, General Manager, Commercial & Integrated Development Operations at Catalent, will share her thoughts about complexities of tech transfers and ensuring a successful product launch. Schedule a Meeting DIA China 2022 | Suzhou, China | July 21-24, 2022 Meet Catalent’s experts at booth E11 to learn more about the trends of globalization and localization affecting drug development and innovation. Schedule a Meeting
Oral & Specialty Delivery
Webinar: Key Considerations for Selection and Encapsulation of Capsules for Dry Powder Inhalation | June 8, 2022
Join this webinar to hear from experts who will be discussing the current market trends in dry powders for inhalation, the key capsule characteristics that determine performance and the fundamental physical characteristics of spray-dried and lactose-based powders that contribute to the efficiency of the encapsulation process. |
|
| A Catalyst in Drug Development |
|
| Lun Xin, M.Sc. Senior Formulation Development Scientist |
|
| Based at Catalent Biologics facility in Bloomington, Indiana, Lun Xin focuses on establishing formulation development and manufacturing capabilities for mRNA-LNP delivery platforms. This newly established facility in Bloomington features fully automated pipetting, buffer exchange, concentration, and a host of analytical assays with high levels of automation and throughput. He collaborates with Catalent’s global data science team to couple the high-throughput formulation development lab with automated data and reporting workflow. He has extensive knowledge of pharmacokinetics, pharmacodynamics, and non-invasive drug delivery as it is applied to biologics. Learn what drives his commitment to research, and access his work on developing high-throughput formulations, fluorescence microscopy detection and more. |
|
|
|
| |
Biologics
Article: " Developing the Next Big Vaccine Technologies" - We are in a new era of possibilities with vaccines. The rapid development of safe and efficacious mRNA vaccines was a triumph for biopharma that has propelled the entire vaccine field–once relegated to the backwaters of biotech R&D–to become a first-class concern of investors and dealmakers. In this executive summary, some of the field’s top experts weigh in on the techniques and technologies they are working on, including self-amplifying RNA, computer-designed nanoparticles, expanding mRNA processes and the challenges of scaling these new technologies. |
|
| Cell & Gene Therapy
Webinar: " Plasmid Platform Facilitates Transition to Clinic" - The demand for plasmid DNA, a critical component to many biological therapeutics, has grown concurrently with advances and successes in cell, gene and mRNA therapies. A plasmid DNA manufacturing platform can support early activities and facilitate the transition towards CGMP production for clinical and commercial supply. Securing the supply of this critical raw material can help biotech and pharma companies throughout the drug development lifecycle of their advanced therapies. |
|
|
|
Clinical Supply Services
Webinar: " Harnessing Parallel Workstreams to Speed Your Biologic into Phase 1-3 Clinical Trials" - The path from drug substance development, through drug product manufacturing and into the clinic is a lengthy and largely linear process. Seeking out opportunities to run workstream activities in parallel through an integrated services approach can significantly shorten the time it takes to get from development into the clinic. This webinar will explore the feasibility of integration and how taking parallel approach enables each activity to be fully executed within a typical vs compressed timeframe, yet enables the overall project timeline to be shortened, often significantly. |
|
| Oral Drug Delivery
Webinar: " Exploring Pectin and the Advancement of Delayed Release Technology" - Recent innovations in oral drug delivery have introduced the use of versatile tools such as pectin, a naturally derived polysaccharide, to enable delayed release properties without the need for coating. In this webinar, experts will provide an overview of why the properties and structure of pectin are well suited for site-specific delivery to the colon. In addition, experts will also provide insights into how softgel capsules, formed by the combination of both pectin and gelatin, are used in OptiGel® DR, a new delayed release delivery technology for pharmaceutical applications. Webinar: " Intranasal Drug Delivery-Identifying Challenges and New Product Opportunities" – Decisions made throughout early and mid-stage clinical trials impact late-stage results and sometimes, entire programs and companies. Since some obstacles can prove overwhelming for startups, there is a lot to learn from those who successfully walked the path. Article: " Emerging Trends and Opportunities in Orally Inhaled Drug Products" - There continues to be a rapid expansion in the orally inhaled therapeutic pipeline, underpinned by scientific, technological, manufacturing and regulatory advances across drug products and devices. In this interview, Catalent experts Carolyn Berg and Carla Vozone discuss innovations in orally inhaled drug products, and in particular dry powders for inhalation. |
|
| Consumer Health
Webinar: "New Entrants in Self-Care" - New competitors are entering and disrupting the status quo of the consumer self-care market. During the COVID-19 pandemic, sales in many over-the-counter (OTC) categories fell considerably. In response, big consumer health players markedly scaled back investments in M&A, while consumer packaged goods (CPG) multinationals and regional companies made further inroads into consumer health. During this webinar, experts in consumer health discuss why new market dynamics are creating opportunities for existing players, and how Catalent can help companies build out brand portfolios and access the market quickly. Webinar: " New Experiences in Supplements" - In the dietary supplements market, several factors affect the consumer’s experience, with one of the most influential and important being the delivery format. There has been a notable shift in how consumers want to take their supplements; with ‘enjoyment’ and ‘the experience’ of taking certain products now taking center stage. In this webinar, learn how this trend will affect the growth of the supplement market now and in the future. Webinar: " New Experiences in Beauty" - Many factors influence consumers’ decisions on the beauty products they will buy. Whether conserving a product’s potency so that it is delivered at full strength, or that the product is manufactured and delivered in a sustainable way, the market is rapidly evolving towards products that provide meaningful, and even delightful experiential benefits alongside function. In this webinar, we will look deeper at the trends and innovations in consumer experiences of the topical beauty market, and the lasting impact of this trend on the market. |
|
| | | Cell and Gene Therapy
In this 360° Virtual Tour, explore Catalent’s Houston clinical development and manufacturing facility for cell therapies. The state-of-the-art facility, at approximately 32,000 sq. ft., houses 8 CGMP clean rooms, 2 tech transfer labs, and fill/finish services. The site has broad cell type expertise across immunotherapies and stem cells for both autologous and allogeneic cell therapy programs.
|
|
| We are the Catalyst for your success. Join us! |
|
| Catalent ignites the development of their future leaders by continuously investing in their employees and creating an innovative environment to advance their potential. We are growing rapidly across sites in Bloomington, Indiana; Madison, Wisconsin; Harmans, Maryland; Kansas City, Missouri; and elsewhere.
Visit www.catalent.com/careers for more information. |
|
| | |
|
Every molecule has a challenge. We have a solution.
|
|
| | | or call +1 877 891 9609 to speak with one of our experts today! |
|
| | |
|
To unsubscribe or manage your subscriptions, please click here.
For more information call +1-866-720-3148 or in Europe 00800 88 55 6178, email us at sales@catalent.com, or visit our website www.catalent.com. And to learn more about Career opportunities across our global network, visit www.catalent.com/careers.
Catalent Pharma Solutions respects your privacy.
Links to third party sites are provided as a convenience only. Catalent makes no representation or warranty about the technology, security or any content available at these sites. Links are not intended to imply Catalent's affiliation or endorsement of the website, its owner(s) or the content.
© 2022, Catalent Pharma Solutions, Inc. 14 Schoolhouse Road, Somerset, NJ 08873. All rights reserved.
|
|
|
|
|
